News

NEWS
Press-Release
August 15, 2018
InSysBio creates a legal entity in UK
InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, today announced the registration of legal entity in UK. InSysBio UK (INSYSBIO UK LIMITED) is located in Edinburgh.
LEARN MORE
NEWS
Press-Release
June 13, 2018
InSysBio Announces Collaboration on Quantitative System Pharmacology Modeling of Chronic Obstructive Pulmonary Disease
InSysBio LLC (www.insysbio.com), a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a collaboration with GSK, one of the world's leading research-based pharmaceutical and healthcare companies, for development of QSP platform of Chronic Obstructive Pulmonary Disease (COPD).
LEARN MORE
NEWS
Press-Release
April 26, 2018
InSysBio, LLC Announces Extension of Collaboration with GSK on Quantitative Systems Pharmacology Modeling in Asthma
InSysBio LLC (www.insysbio.com) – pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development – announced today further collaboration with GSK - one of the world's leading research-based pharmaceutical and healthcare companies - to expand the previously developed QSP model of asthma.
LEARN MORE
NEWS
Publication
February 26, 2018
InSysBio modelers evaluated tau protein phosphorylation related targets for Alzheimer’s disease treatment
InSysBio continues to investigate the mechanisms underlying Alzheimer’s disease (AD) using the quantitative systems pharmacology (QSP) modeling approach. The part of QSP model describing tau protein was published in the PLOS ONE journal. This is one of more than dozen InSysBio publications in AD area during last seven years.
LEARN MORE
NEWS
Conference
February 20, 2018
InSysBio Annual Internal Scientific Meeting
14-16 February 2018 InSysBio held Annual Internal Scientific Meeting.
LEARN MORE
NEWS
Press-Release
September 28, 2017
Computer model showed an optimal anti-amyloid treatment
Moscow, Russia, September 28, 2017. One must activate amyloid degradation as soon as possible to prevent the appearance of the protein plaques in brain under Alzheimer’s conditions. This conclusion was reached by scientists from the biotechnology company InSysBio, who created the first computer model of the disease. The final part of the work has been recently published in CPT: Pharmacometrics & Systems Pharmacology.
LEARN MORE
January 2025
MoTuWeThFrSaSu
  
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
  
Upcoming Events
Tags